

Original Investigation

Characteristics of nailfold videocapillaroscopy and antinuclear antibodies in a cohort of patients with systemic autoimmune disease with Raynaud's phenomenon[☆]



Andrea Facio-Lince García^a, Carlos Jaime Velásquez-Franco^{a,b,c,*},
Aura Ligia Zapata-Castellanos^{a,b,c}, Libia María Rodríguez-Padilla^{a,b,c},
Miguel Antonio Mesa-Navas^{a,b,c}

^a Facultad de Medicina, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

^b Grupo de Investigación UNIR, Escuela de Ciencias de la Salud, Universidad Pontificia Bolivariana, Medellín, Colombia

^c Servicio de Reumatología, Clínica Universitaria Bolivariana, Medellín, Colombia

ARTICLE INFO

Article history:

Received 24 November 2017

Accepted 13 June 2018

Available online 26 February 2019

Keywords:

Raynaud's disease

Microscopic angiopathy

Antinuclear antibodies

Autoimmune diseases

ABSTRACT

Introduction: Between 15% and 20% of patients with Raynaud's phenomenon will progress to a systemic autoimmune disease. The presence of autoantibodies or capillaroscopy alterations are fundamental for early diagnosis.

Objectives: To determine the characteristics of nailfold videocapillaroscopy and antinuclear antibodies in a cohort of patients with systemic autoimmune disease.

Materials and methods: A cross-sectional study was conducted in subjects with Raynaud's phenomenon. These were evaluated with videocapillaroscopy and antinuclear antibodies. The qualitative variables were described with absolute and relative frequencies. The quantitative variables, according to the distribution of data, were reported as mean or median, with standard deviation and interquartile range, respectively.

Results: The study included 58 individuals, of which 91.4% were women. The mean age was 40.9±14.1 years. Antinuclear antibodies were positive in 41 subjects. The most common pattern was speckled (41.5%), with a median dilution of 1:640 (interquartile range 1:320–1:1280). A systemic autoimmune disease was found in 10 (19.2%) patients, 8 of them with systemic sclerosis. The most frequent capillary alterations were: mega-capillaries (n=10), micro-hemorrhages (n=10), and avascular zones (n=8).

PII of original article: S0121-8123(18)30061-6

[☆] Please cite this article as: Facio-Lince García A, Velásquez-Franco CJ, Zapata-Castellanos AL, Rodríguez-Padilla LM, Mesa-Navas MA. Características de la videocapilaroscopia del lecho ungular y de los anticuerpos antinucleares en una cohorte de pacientes con enfermedad autoinmune sistémica con fenómeno de Raynaud. Rev Colomb Reumatol. 2018;25:169–176.

* Corresponding author.

E-mail address: carjaivel@gmail.com (C.J. Velásquez-Franco).

2444-4405/© 2018 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Conclusions: In this group of patients with Raynaud's phenomenon subjected to videocapillaroscopy, a diagnosis of systemic autoimmune disease was made in a similar percentage to that reported in the literature. A higher dilution of antinuclear antibodies was found than that described.

© 2018 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Características de la videocapilaroscopia del lecho ungular y de los anticuerpos antinucleares en una cohorte de pacientes con enfermedad autoinmune sistémica con fenómeno de Raynaud

R E S U M E N

Palabras clave:

Enfermedad de Raynaud
Angioscopia microscópica
Anticuerpos antinucleares
Enfermedades autoinmunes

Introducción: Entre un 15 y un 20% de los pacientes con fenómeno de Raynaud progresarán a una enfermedad autoinmune sistémica. La presencia de autoanticuerpos o alteraciones capilaroscópicas es fundamental para el diagnóstico temprano.

Objetivos: Determinar las características de la videocapilaroscopia del lecho ungular y de los anticuerpos antinucleares en una cohorte de pacientes con enfermedad autoinmune sistémica.

Materiales y métodos: Se realizó un estudio transversal en sujetos con fenómeno de Raynaud. Estos fueron evaluados con videocapilaroscopia y anticuerpos antinucleares. Las variables cualitativas se describieron con frecuencias absolutas y relativas; las variables cuantitativas, según la distribución de los datos, se reportaron como media o mediana, con desviación estándar y rango intercuartílico, respectivamente.

Resultados: Se incluyeron 58 individuos; el 91,4% eran mujeres. La edad promedio fue $40,9 \pm 14,1$ años. En 41 sujetos, los anticuerpos antinucleares fueron positivos; el patrón más común fue el moteado (41,5%), con una mediana de dilución de 1:640 (rango intercuartílico 1:320-1:1.280). Se encontró enfermedad autoinmune sistémica en 10 individuos (19,2%), 8 de ellos con esclerosis sistémica. Las alteraciones capilares más frecuentes fueron: megacapilares ($n = 10$), microhemorragias ($n = 10$) y zonas avasculares ($n = 8$).

Conclusiones: En este grupo de pacientes con fenómeno de Raynaud sometidos a videocapilaroscopia, el diagnóstico de enfermedad autoinmune sistémica fue realizado en un porcentaje similar a lo reportado en la literatura. Se encontró una mayor dilución de anticuerpos antinucleares que la descrita.

© 2018 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Raynaud's phenomenon (RP) is defined as a vasospasm secondary to an alteration of the capillary microvasculature, which causes episodes of cyanosis, pallor, and reactive erythema.¹ The prevalence of RP among the general population ranges between 3% and 5% and is divided into: primary (not associated to the systemic disease) and secondary (to metabolic, vascular, neoplastic or rheumatologic diseases). The secondary causes account for approximately 20% of the cases of RP.²

Among the causes of secondary RP, systemic autoimmune diseases (SADs) are the most frequent (systemic sclerosis, systemic lupus erythematosus, Sjögren syndrome, mixed connective tissue disease, systemic vasculitis, and inflammatory myopathies, inter alia.)³ Among this group of conditions, RP is often the sentinel event (this is the case in 90% of individuals with systemic sclerosis and in 85% of patients with mixed connective tissue disease)^{4,5}

In SADs, the behavior of RP is aggressive and may lead to local complications (ulcers, necrosis, and finger over-infection) with impending risk of amputation. Additionally, RP is associated in these diseases with visceral organ involvement (particularly pulmonary arterial hypertension), a manifestation with a significant morbidity and mortality.^{6,7}

Considering the importance of differentiating primary from secondary RP, one of the non-invasive techniques, which is reproducible and effective to assess microcirculation is nailfold videocapillaroscopy (NVC)⁸; this procedure identifies morphological abnormalities such as capillary architecture disorders, increased diameter of the capillaries, hemorrhage, reduced number of capillaries, and angiogenesis, all of which are indicative of endothelial damage. Already in 2013, the *European League Against Rheumatism* and the *American College of Rheumatology* included NVC in the classification criteria for systemic sclerosis.⁹ This method, together with antinuclear antibodies (ANA), allows for the identification of patients that will progress to SAD between 2 and 10 years in advance.^{7,10} This early identification of SAD allows for a strict surveillance

of the patient and for establishing screening strategies for visceral organic involvement, improving treatment and leading to a positive impact on morbidity and mortality.

Most of the papers available on NVC and SAD were designed as predictive models and only focus on the capillaroscopic findings with medium term follow-up¹¹⁻¹⁵; following an extensive literature search, no information on the topic was found in Latin America. The databases consulted were: Scielo, Pubindex, Latindex, Imbiomed, Lilacs. The terms used for searching in English and Spanish, from 2010 through 2017, were: Raynaud's disease, microscopic angiopathy, antinuclear antibodies, and autoimmune diseases.

The objective of this study was to determine the characteristics of NVC and of ANA, in a cohort of patients with SAD, in the North Western region of Colombia.

Methods

Design and study population

A cross-sectional study was conducted in patients with RP, at a high complexity center and regional referral institution for NVC in the North Western region of Colombia. The patients that met the current international consensus criteria for the classification of RP,¹⁶ between October 2015 and September 2016, were over 18 years old, accepted to voluntarily participate in the trial, and signed the informed consent.

The specific eligibility criteria to establish the presence of RP were based on a positive answer to the following questions¹⁶:

- Are your fingers unusually sensitive to cold?
- Do biphasic color changes occur during the episodes of vasospasm?

And meeting at least 3 of the following 7 criteria:

- Presence of precipitating factors other than cold
- Involvement of both hands, even if asynchronous and asymmetrical
- Episodes accompanied by dysesthesias or paresthesias
- Persisting color changes, with a well demarcated margin between the affected and the non-affected skin
- Matching patient photographs
- Episodes presenting in various parts of the body (nose, auricles, areolas, feet)
- Tri-phasic color changes during the episodes

The following were the exclusion criteria:

- Active smoking (any amount of tobacco use)
- Having been previously diagnosed with SAD
- Secondary causes (vasculitis, primary vascular diseases, hematological conditions, solid neoplasms, neurovegetative causes, central nervous system and endocrine diseases, medicines, and toxic substances).

Data collection process

Upon endorsement of the health research committee of the participating institution, all subjects underwent an NVC using an Optilia machine and a 200× lens with OptiPix software (Optilia Instruments; Sollentuna, Switzerland), checking for compliance with the requirements prior to the procedure, including: clean nails free from any substances that limit the visibility of the capillary bed (nail polish, acrylics, gels), or manipulation of the cuticle (manicure, onychophagia) 2 weeks prior to the NVC.

The procedure was conducted in keeping with the international standards: assessment of fingers from the index to the little finger of both hands, in a room at room temperature (26–32 °C), prior application of almond oil; 4 consecutive pictures were taken from each finger in the central region.¹⁷ Extreme pressure on the nail surface was avoided, to prevent interrupting the blood flow and altering the pictures. The first raw of the capillary loops were assessed, counted, and measured in accordance with the international parameters.¹⁶

The NVC was conducted and interpreted by two rheumatologists, certified by the Service of Capillaroscopy of the University of Genoa (Italy), who before the beginning of this research participated in a test for standardizing the capillaroscopic classification of patterns and findings, in order to ensure interobserver concordance. This test included 100 blinded images randomly selected, from both healthy controls and patients with some capillaroscopic alteration; the kappa coefficient in this standardization was 0.84 (95% CI 0.66–1.0), scored as very good. The semi-quantitative method described by Sulli et al.,¹⁸ validated in a reference cohort, was used to score the capillary findings (quantity, abnormal size increase, megacapillaries, microbleedings, ramifications and disorganization).¹⁹

With regards to laboratory tests, the erythrocyte sedimentation rate (ESR) and ANAs were conducted at a referral laboratory, using the conventional techniques (Westergren and indirect immunofluorescence, respectively).

At the time of capillaroscopy, the investigators collected the information about the target variables for this trial from the case history, the physical examination, the NVC findings and lab tests records. A data collection electronic form was designed using MagPi™, and a pilot test was conducted including the first 10 patients, with a view to estimate the time required to gather the information and to make the necessary changes, ensuring the reliability of the process.

The following variables were collected: demographic and epidemiological (age, gender, personal history, family history of RP or SAD); RP-related (starting date, phases, annual frequency of outbreaks, date of last outbreak); paraclinical tests (ESR, ANA); capillaroscopic (number of capillaries/mm, presence of hemorrhages, megacapillaries, neovascularization, and pattern), according to the current nomenclature,²⁰ and SAD diagnosis (systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, undifferentiated connective tissue disease, inflammatory myopathies, rheumatoid arthritis, Sjögren's syndrome, and antiphospho-

pholipid syndrome), pursuant to the current classification criteria,²¹ confirmed by the participating rheumatologists.

Upon completion of the data collection process, the information was transferred to an electronic spread sheet in Microsoft Excel[®] 2010, where some of the variables were recoded as needed, and the consistency of the data was verified before doing the analysis.

In order to control any potential biases, the following strategies were used: a discussion was organized among the protocol and data collection process investigators; the database was developed with restricted fields to avoid data input errors; furthermore, the quality of the data was assessed every week, internal consistency was checked, and in case of doubt, primary source confirmation was conducted. With regards to ANAs, only the dilutions $\geq 1:320$ were considered, where only 3% of the general population would have this level of dilution of antibodies.

Statistical analysis

In the standardization test prior to this trial, the interobserver concordance to read the capillaroscopic patterns (normal, minor and non-specific alterations and systemic sclerosis) was determined estimating the quadratic weighted kappa coefficient and its corresponding confidence interval. This coefficient was interpreted in accordance with the following guidelines offered by Landis and Koch: poor or weak, for values below 0.40; moderate for values between 0.41 and 0.60; good or strong between 0.61 and 0.80; and excellent or almost perfect for values between 0.81 and 1.²² The interobserver agreement was 0.84 (0.66–1.0), considered excellent.

The qualitative variables were described as absolute and relative frequencies; the quantitative variables, according to the distribution of the data, were reported as means and medians, with standard deviation and interquartile range (IQR), respectively.

Ethical considerations

This research is considered with minimal risk and received the institutional ethical endorsement of the project and the informed consent of each participant.

Results

General characteristics

239 patients were assessed over the study period, of which 58 met the eligibility criteria; 53 (91.4%) were females. The average age was 40.9 ± 14.1 years; the time of evolution of the RP was in average 3.1 years (IQR 3.1–8.9). Other characteristics of the subjects are shown in Table 1.

Paraclinical findings

In 41 of 55 individuals (70.7%), the ANAs were positive; the most frequent patterns were: mottled and centromeric (Fig. 1). The information about the ANA dilutions was available in 36 subjects and among them the median was 1:640 (IQR

Table 1 – Clinical and demographic characteristics of a cohort of patients with Raynaud's Phenomenon.

Characteristic	n/N (%)
Sex female	53/58 (91,4)
Age (years)	40.9±14.1 ^a
Family history	14/58 (24.1)
Rheumatoid arthritis	6/14 (42.9)
Lupus	6/14 (42.9)
Sjögren syndrome	1/14 (7.1)
Other	1/14 (7.1)
Number of phases	
One	8/58 (13.8)
Two	35/58 (60.3)
Three	12/58 (20.7)
Pallor	25/58 (43.1)
Cyanosis	21/58 (36.2)
Erythema	11/58 (19.0)
Number of episodes per month (n = 55)	30 (8–30) ^b

^a Mean ± standard deviation.

^b Median (Interquartile range).




Fig. 1 – Patterns of antinuclear antibodies in a cohort of patients with Raynaud's Phenomenon.

1:320–1:1280). With regards to ESR, the median was 9 mm/h (IQR 4–13).

Presence of systemic autoimmune disease

SAD was identified in 10 patients (19.2%): 7 individuals with limited systemic sclerosis, 2 with mixed connective tissue disease, and one with diffuse systemic sclerosis. In the case of the 7 patients with limited systemic sclerosis; the diagnosis was based on compliance with the systemic sclerosis classification criteria ACR/EULAR 2013: sclerodactyly, RP, capillaroscopic abnormalities, and positive related autoantibodies. In the case of diffuse systemic sclerosis, the following criteria were met: proximal cutaneous thickening of the metacarpal-phalangeal joints, RP, capillaroscopic abnormalities and positive related antibodies. In the 2 subjects with a diagnosis of mixed connective tissue disease, the Kahn and Alarcón-Segovia criteria were met (positive anti-RNP, diffuse hand and finger edema, synovitis, and RP).

When describing some of the patients' characteristics based on the presence or absence of SADs, none of the patients with SAD were found to present monophasic RP and

Table 2 – Antinuclear antibodies profile in a cohort of patients with systemic autoimmune disease and Raynaud's phenomenon.

	Limited systemic sclerosis (n = 7)	Diffuse systemic sclerosis (n = 1)	Mixed connective tissue disease (n = 2)
ANA positive	6	1	2
ANA pattern			
Mottled	1	1	1
Centromeric	4		1
Nucleolar	1		

Table 3 – Capillaroscopic findings in a cohort of patients with Raynaud's phenomenon.

Parameters	Total (n = 58)	Systemic autoimmune disease (n = 10)	Without systemic autoimmune disease (n = 42)
	n (%)	n (%)	n (%)
Pattern			
Normal	28 (48.3)	0	25 (59.5)
Unspecific alterations	16 (27.6)	2 (20)	12 (28.5)
Systemic sclerosis pattern			
Active	5 (8.6)	3 (30)	1 (2.4)
Early	5 (8.6)	3 (30)	2 (4.8)
Late	2 (3.4)	2 (20)	0
“Scleroderma-like”	2 (3.4)		2 (4.8)

the frequency of biphasic RP was higher among the subjects with SAD as compared against patients without SAD (80 vs. 60%). The cyanotic phase was the most frequent in patients with SAD (60 vs. 31.3%). The profile of ANA pattern in these subjects is illustrated in Table 2. Among this group of patients, the dilution of ANAs was available in 9 of them; the median was 2:1280 (IQR 1:640–1:2560).

Capillaroscopic findings

The most frequent capillaroscopic alterations in patients with SAD were: presence of megacapillaries (n = 10), microhemorrhages (n = 8), avascular areas (n = 8), neovascularization (n = 6), and capillary disorganization (n = 6). The capillary diameter could be measured in 54 patients of the cohort, with a median of 25 μm (IQR 16–48).

In the 8 patients with systemic sclerosis, the largest capillary diameter identified was 72.4 μm (standard deviation 33.8); the median for the number of capillaries per millimeter was 7 (IQR 6–8) in the subjects with limited systemic sclerosis. The capillaroscopic patterns in the total cohort of patients and in the subgroups, based on the presence or absence of SAD is illustrated in Table 3. In the SAD-free subjects, the capillaroscopy was normal in 60% of the cases; in individuals with SAD, 80% had an active and late systemic sclerosis pattern.

Fig. 2 illustrates the normal capillaroscopic findings in subjects with primary RP; Figs. 3–5 show the patterns and the most striking abnormalities in patients with a diagnosis of SAD.

Discussion

The major finding in this trial was that in patients with RP, SAD was identified in 19.2% of the cases, with particular findings in the NVC and in the ANA. This is a striking result that has not been widely explored in the literature. Most of the information focuses on prognostic and transition models



Fig. 2 – Capillaroscopy in primary Raynaud's phenomenon: capillaries in inverted “U” shape, with uniform spaces between the capillaries and without hemorrhages, megacapillaries, or neovascularization (Optilia 200 \times magnification capillaroscope).




Fig. 3 – Early pattern of systemic sclerosis: presence of megacapillary (capillary with a diameter >50 μm – arrow) (Optilia 200 \times magnification capillaroscope).

of primary to secondary RP that include these diagnostic tools.^{12,13} Bernero et al. analyzed 2065 patients with primary RP, and found that 565 (27.3%) of them had basal



Fig. 4 – Presence of active systemic sclerosis pattern: larger number of megacapillaries and hemorrhages – arrow (Optilia 200× magnification capillaroscope).



Fig. 5 – Presence of late systemic sclerosis pattern (presence of neovascularization and avascular areas – arrow (Optilia 200× magnification capillaroscope).

videocapillaroscopic findings, but no description is made about these findings, and the ANA are not mentioned either.²³ Secchi et al. conducted a study in 120 Italian patients with primary RP; the videocapillaroscopy presented non-specific findings in 10% but the findings were not clearly explained and there was no information about the antibody profile.²⁴

With regards to the characteristics of this cohort, they were similar to what is published in the literature; Moinzadeh et al., in a study with 569 subjects, reported an average age of 43±13 years, 85% females,²⁵ similar to the data reported by Pavlov-Dolijanovic et al.¹⁴ The major difference in this paper versus those series was the shorter time of evolution of RP (median of 13 years in the paper by Moinzadeh and 5.3 years in the Pavlov-Dolijanovic's cohort); it is believed that the reason for this difference could be that in Colombia, a tropical country, and Medellín – a temperate climate city – the development of RP usually gives rise to a diagnostic investigation and the patients are referred earlier as compared to patients in Europe, where RP is more frequent because of the seasonal variations, and only subjects with alarm signs are referred.

Likewise, among the criteria for primary RP, being younger than 25-years old was part of the diagnosis, but although this clinical information serves as a guide, it is not indispensable.¹⁶ The results of this paper ratify this statement, since patients at the onset of RP were older and there were significant differences between patients with and without SAD. Other characteristics such as the number of RP phases and the number of monthly crisis, are similar to what is reported in the literature.

The high frequency of ANA is significant in this cohort. Wollersheim et al., in 101 patients with RP, found positive ANA in 28%²⁶; this difference could be explained by the techniques used to identify the presence of antibodies (indirect immunofluorescence in this study, versus immunoblot in Wollersheim et al. trial). Although this frequency is striking, we should not forget that ANA have a very low specificity for the diagnosis of primary RP and are no longer part of the classification criteria¹⁶; moreover, ANA may be present in up to 30% of the general population, at titers of 1:40.²⁷

Another significant finding were the high ANA titers in patients with SAD; this finding indicates that higher ANA dilutions represent an increased probability of SAD, and the likelihood of having these titers present in the general population is less than 3%.²⁴ This finding is also consistent with the report by Hirschl et al., that found that ANA titers >1:320 were associated with a higher risk of developing a SAD in patients with RP.²⁸

The finding of a normal ESR in the general cohort of patients with RP and in the group of subjects with SAD was also surprising. It has always been said, following the criteria by LeRoy and Medsger in 1992,²⁹ that a normal ESR was associated with primary RP and abnormal values pointed to secondary RP. However, the current classification criteria exclude this paraclinical variable, because of its low specificity.¹⁶

The specific capillaroscopic findings in subjects with SAD are also highlighted; the results obtained in this study are similar to what is published in the literature. Koenig et al.,¹⁰ described the most frequent basal alterations in individuals with a diagnosis of early systemic sclerosis, including: the presence of megacapillaries, the moderate or severe loss of capillaries, and the isolated telangiectasia. No differences were found either with regards to the capillaroscopic patterns; these were compatible with the most usual diagnosis of SAD, which was systemic sclerosis. Moreover, the individual findings correspond to the chronological sequence described by Cutolo et al.: early development of megacapillaries and hemorrhages; then there was an increase in both (active pattern), and finally loss of capillaries, disorganization of the architecture, and neovascularization (late pattern).³⁰

A striking finding was the presence in 2 subjects of mixed connective tissue disease, where RP is part of the classification criteria, as well as systemic sclerosis. A Brazilian series described capillaroscopic alterations in 63 patients using stereomicroscopy; 65% of them had a "scleroderma-like" pattern, with the presence of few avascular areas; the capillaroscopic findings in the subjects in this study are consistent with this description.³¹

Furthermore, analyzing the behavior of the ANA with the NVC findings, greater dilutions were found in patients with

SAD and pathological capillaroscopic changes, a finding ratified by Schlager et al. in a series of 2971 patients, of which 26.9% had positive ANA with a dilution $\geq 1:160$ and of these, 29.5% with capillaroscopic abnormalities. There was a correlation between the ANA and the presence of avascular areas, megacapillaries, pericapillary edema, reduce capillary density, ramifications, hemorrhages and dilatations.³² Moinzadeh et al.²⁵ analyzed 569 patients with isolated RP. During the baseline visit, 7% of these subjects were identified with positive ANA and 17% had more than 3 alterations in the videocapillaroscopy. Moreover, 7 out of 8 individuals that developed systemic sclerosis had a capillaroscopic pattern compatible with this diagnosis and positive ANA; both tools are essential for the diagnosis of this condition.⁹

The strengths of this paper include: as far as we know, this is the first series of Colombian patients describing the presence of SAD in patients with primary RP, with particular ANA and NVC characteristics. Strict and validated classification criteria were used; the capillaroscopic evaluation was conducted by 2 rheumatologists certified in this tool.

We have to acknowledge the limitations inherent to the design of the study, since in order to make the specific diagnosis of SAD, clinical and paraclinical monitoring are critical. Currently, a follow-up study of this same cohort is being conducted that will contribute with additional information about the clinical and paraclinical behavior of these subjects.

Conclusions

In a cohort of patients with RP that underwent NVC, SAD was identified in 19.2%, a frequency similar to the numbers reported in the literature. A high dilution of ANA was also found in patients with SAD, which is above the level reported in different series.

Financing

The Universidad Pontificia Bolivariana and the Colombian Association of Rheumatology, through research announcements. This paper was not sponsored by scholarships or funding from the pharmaceutical industry.

Conflict of interest

The authors have no conflict of interest to disclose.

Acknowledgments

To the patients participating in the study who significantly contributed to an enhanced knowledge of the systemic autoimmune diseases.

To the Colombian Association of Rheumatology for the economic support through the 2015 Research Announcement.

To the participating institutions.

REFERENCES

1. Wigley FM. Raynaud's phenomenon. *N Engl J Med*. 2002;347:1001-8.
2. Linnemann B, Erbe M. Raynaud's phenomenon: assessment and differential diagnoses. *Vasa*. 2015;44:166-77.
3. Lambova SN, Müller-Ladner U. The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports. *Rheumatol Int*. 2009;29:1263-7.
4. Grader-Beck T, Wigley FM. Raynaud's phenomenon in mixed connective tissue disease. *Rheum Dis Clin North Am*. 2005;31:465-81.
5. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: Evidence that systemic sclerosis is a vascular disease. *Arthritis Rheum*. 2013;65:1953-62.
6. Cavagna L, Codullo V, Ghio S, Scirè CA, Guzzafame E, Scelsi L, et al. Undiagnosed connective tissue diseases: high prevalence in pulmonary arterial hypertension patients. *Medicine (Baltimore)*. 2016;95:e4827.
7. Kayser C, Sekiyama JY, Próspero LC, Camargo CZ, Andrade LE. Nailfold capillaroscopy abnormalities as predictors of mortality in patients with systemic sclerosis. *Clin Exp Rheumatol*. 2013;31 Suppl 76:103-8.
8. Cutolo M, Sulli A, Secchi ME, Olivieri M, Pizzorni C. The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases. *Best Pract Res Clin Rheumatol*. 2007;21:1093-108.
9. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. *Ann Rheum Dis*. 2013;72:1747-55.
10. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum*. 2008;58:3902-12.
11. Ziegler S, Brunner M, Eigenbauer E, Minar E. Long-term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. *Scand J Rheumatol*. 2003;32:343-7.
12. Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). *Arthritis Rheum*. 2008;58:2174-82.
13. Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C, et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. *Rheumatology*. 2010;49:797-805.
14. Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, Vujasinovic Stupar NZ, Stanisavljevic DM. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. *Rheumatol Int*. 2012;32:3039-45.
15. Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR. Predictive value of nailfold capillaroscopy in patients with

- Raynaud's phenomenon. *Clin Rheumatol.* 2006;25:153-8.
16. Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allamore Y, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. *J Autoimmun.* 2014;48-49:60-5.
 17. Etehad Tavakol M, Fatemi A, Karbalaie A, Emrani Z, Erlandsson BE. Nailfold capillaroscopy in rheumatic diseases: which parameters should be evaluated? *Biomed Res Int.* 2015;2015:974530.
 18. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. *Ann Rheum Dis.* 2008;67:885-7.
 19. Smith V, Pizzorni C, de Keyser F, Decuman S, van Praet JT, Deschepper E, et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. *Ann Rheum Dis.* 2010;69:1092-6.
 20. Smith V, Thevissen K, Trombetta AC, Pizzorni C, Ruaro B, Piette Y, et al., EULAR Study Group on Microcirculation in Rheumatic Diseases. Nailfold capillaroscopy and clinical applications in systemic sclerosis. *Microcirculation.* 2016;23:364-72.
 21. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. *Lancet.* 2013;382:797-808.
 22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977;33:159-74.
 23. Bernero E, Sulli A, Ferrari G, Ravera F, Pizzorni C, Ruaro B, et al. Prospective capillaroscopy-based study on transition from primary to secondary Raynaud's phenomenon: preliminary results. *Reumatismo.* 2013;65:186-91.
 24. Secchi ME, Sulli A, Grollero M, Pizzorni C, Parodi M, Paolino S, et al. [Role of videocapillaroscopy in early detection of transition from primary to secondary Raynaud's phenomenon in systemic sclerosis] Italian. *Reumatismo.* 2008;60:102-7.
 25. Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. *Clin Rev Allergy Immunol.* 2012;43:249-55.
 26. Wollersheim H, Thien T, Hoet MH, van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. *Eur J Clin Invest.* 1989;19:535-41.
 27. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. *Arch Pathol Lab Med.* 2000;124:71-81.
 28. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. *Arthritis Rheum.* 2006;54:1974-81.
 29. LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. *Clin Exp Rheumatol.* 1992;10:485-8.
 30. Cutolo M, Sulli A, Pizzorni C, Acardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. *J Rheumatol.* 2000;27:155-60.
 31. De Holanda Mafaldo Diógenes A, Bonfá E, Fuller R, Correia Caleiro MT. Capillaroscopy is a dynamic process in mixed connective tissue disease. *Lupus.* 2007;16:254-8.
 32. Schlager O, Kiener HP, Stein L, Hofkirchner J, Zehetmayer S, Ristl R, et al. Associations of nailfold capillary abnormalities and immunological markers in early Raynaud's phenomenon. *Scand J Rheumatol.* 2014;43:226-33.